Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Restricted Share Units | 53.5K | $8.68M | $162.16 | May 1, 2024 | Direct |
JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Restricted Share Units | 50.5K | $8.34M | $165.06 | May 1, 2024 | Direct |
JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Employee Stock Options (Right to Buy) | 65.2K | $5.89M | $90.44 | Feb 15, 2024 | Direct |
JOHNSON & JOHNSON | EVP, Innovative Medicine, R&D | Common Stock | 14.6K | $2.11M | $144.59 | May 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
JNJ | JOHNSON & JOHNSON | May 1, 2024 | 3 | -$1.59M | 4/A | Oct 31, 2024 | EVP, Innovative Medicine, R&D |
JNJ | JOHNSON & JOHNSON | Feb 15, 2024 | 2 | $0 | 4 | Feb 20, 2024 | EVP, Innovative Medicine, R&D |
JNJ | JOHNSON & JOHNSON | May 1, 2023 | 1 | $0 | 4 | May 2, 2023 | EVP, Pharmaceuticals R&D |
JNJ | JOHNSON & JOHNSON | Apr 3, 2023 | 0 | $0 | 3 | Apr 13, 2023 | EVP, Pharmaceuticals R&D |